GPX4 and breast carcinoma: For instance, direct pharmacological inhibition of GPX4’s enzymatic activity with agents like RSL3, or depletion of GSH by blocking the upstream transporter SLC7A11 with inhibitors such as erastin, both lead to a sharp increase in intracellular LOOH levels in breast cancer cells [73,74].